507 results about "Acid derivative" patented technology

A method for improving health conditions of mammals or livestock by feeding, to the mammals or livestock, a licorice extract including: (A) glycyrrhizic acid, a glycyrrhizic acid derivative, glycyrrhetinic acid, and / or a glycyrrhetinic acid derivative; (B) licorice saponins other than (A); and (C) licorice flavonoids; (B) including at least a licorice saponin H2, a licorice saponin G2, and macedonoside A, (C) including at least liquiritin apioside, isoliquiritin apioside, and isoliquiritin, where feeding is of 0.017 g / day / head or more of the licorice saponin H2, 0.002 g / day / head or more of the licorice saponin G2, and 0.002 g / day / head or more of the macedonoside A, 0.001 g / day / head or more of the liquiritin apioside, 0.001 g / day / head or more of the isoliquiritin apioside, and 0.001 g / day / head or more of the isoliquiritin.

The invention belongs to the technical field of polymer synthetic materials, and particularly relates to bio-based MS resin and a preparation method thereof. The bio-based MS resin is a free radical copolymer of a methyl methacrylate monomer and a styrene monomer; the methyl methacrylate monomers comprise bio-based methyl methacrylate, isobornyl methacrylate and 3-pinane methacrylate, and the methyl methacrylate monomers comprise methyl methacrylate, isobornyl methacrylate and 3-pinane methacrylate; the styrene monomers comprise styrene and caffeic acid derivatives; based on 100% of the mass of the bio-based MS resin, the methacrylate monomer accounts for 30%; the molar ratio of caffeic acid derivatives to styrene in the styrene monomers is 1: (1-9). The synthesized bio-based MS resin has the characteristics of greenness and reproducibility, compared with petroleum-based MS resin, the performance of the MS resin can be regulated and controlled by designing a protecting group of a bio-based caffeic acid derivative so as to expand the application range of the MS resin, a specific functional group can be introduced to prepare a functional, advanced and high-performance polymer material, and the MS resin has a good market prospect.

The invention discloses an oil-controlling and acne-removing synergistic composition which comprises the following components in percentage by weight: 0.8 to 2.0 percent of succinic acid, 0.3 to 1.0 percent of salicylic acid derivative and 0.5 to 1.5 percent of PCA (Principal Component Analysis) zinc. The invention also provides a sustained-release body. The sustained-release body is prepared from the following components in percentage by weight: 0.8 to 2.0 percent of succinic acid, 0.3 to 1.0 percent of salicylic acid derivative, 0.5 to 1.5 percent of PCA zinc, 1.0 to 2.5 percent of lactobionic acid, 1.0 to 3.0 percent of lactobacillus fermentation product, 2.0 to 4.0 percent of aminated modified diatomite and 0.1 to 0.3 percent of citric acid. The invention also provides a preparation method and application of the sustained release body. The acne-removing shampoo has low irritation, and can be used for controlling oil and removing acnes for a long time and efficiently dredging hair follicles.

Provided are: a liquid crystal aligning agent which contains two or more polyamic acids and in which deterioration in liquid crystal aligning properties when stored at room temperature is suppressed; a liquid crystal alignment film obtained from the liquid crystal aligning agent; and a liquid crystal display element. The liquid crystal aligning agent is characterized by containing the following polymer (A) and polymer (B). Polymer (A): a polyamic acid (A) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (a-1Ta) represented by formula (1Ta), and containing, as the structural unit derived from the diamine, a structural unit (a-1Da) represented by formula (1Da), at least a part of the terminal of the polyamic acid (A) contains a non-amino group, the non-amino group is a functional group represented by structural formula (E), and the presence rate of the terminal amino group in the polyamic acid (A) is 60% or less based on the total terminal of the polyamic acid (A). Polymer (B): a polyamic acid (B) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid including a structural unit (b-1Tb) represented by formula (1Tb) as the structural unit derived from the tetracarboxylic acid derivative, and including a structural unit (b-1Db) represented by formula (1Db) as the structural unit derived from the diamine. (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification)

The invention discloses a preserving fluid for stably preserving sample DNA at normal temperature and a preparation method thereof, and belongs to the technical field of biological sample preservation. The preserving fluid comprises a lysis system, a nucleic acid protection system and a buffering and stabilizing system, the cracking system comprises a composite surfactant and an enzymolysis auxiliary agent; the composite surface active agent is prepared from polyether polyol fatty acid ester and cocamidopropyl hydroxy sulfobetaine; the enzymolysis auxiliary agent comprises lysozyme Lyso-V and protease K; the nucleic acid protection system comprises a nitrogen heterocyclic polyamine-carboxylic acid derivative and dextran sulfate; the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N' ', N ''tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N''-triacetic acid, disodium ethylene diamine tetraacetate-nitrogen heterocyclic derivative, and diethylenetriamine pentaacetic acid-piperazine derivative, and the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N '', N'' tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N ''-triacetic acid. The buffering and stabilizing system comprises an amphoteric buffering agent and a polymer stabilizer; the amphoteric buffering agent comprises 2-(N-morpholino) ethanesulfonic acid and N-tri (hydroxymethyl) methylglycine.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention relates to an acridine sulfonamide carboxylic acid derivative as well as a preparation method and application thereof, and the preparation method comprises the following steps: in an alkaline environment, acridine sulfonamide and amino acid or an amino acid derivative are subjected to amidation reaction in an organic solvent, and the acridine sulfonamide carboxylic acid derivative is obtained after purification; wherein the acridine sulfonamide carboxylic acid derivative has two acridine sulfonamide-like groups, and the two acridine sulfonamide-like groups are connected through the amino acid or the amino acid derivative. The yield of the preparation method exceeds 70%, and the luminous efficiency of the prepared acridine sulfonamide carboxylic acid derivative is higher and is about two times that of acridine sulfonamide NSP-SA-NHS.

The invention belongs to the technical field of biological medicines, and particularly relates to a royal jelly acid derivative and a synthesis method, a pharmaceutical composition and application thereof. The royal jelly acid derivative is a compound shown as a formula (I), or an enantiomer, a diastereoisomer and a tautomer thereof, or a solvate or a pharmaceutically acceptable salt thereof. A series of royal jelly acid derivatives with novel structures are constructed by using a natural component royal jelly acid derived from royal jelly as an initial raw material, the royal jelly acid derivatives can play a role in resisting pulmonary fibrosis by inhibiting the activity of fibroblasts, the effect of the royal jelly acid derivatives is equivalent to that of pirfenidone, and the royal jelly acid derivatives are expected to be developed into candidate drugs for resisting pulmonary fibrosis. The ceramide NP has excellent effects in anti-inflammatory, anti-allergic and itching-relieving aspects, has a better effect than known ceramide NP, and can be used for preparing health care products, cosmetics and medicines. And # imgabs0 #.

The invention belongs to the technical field of catalytic methods and catalysts, and particularly relates to a method for preparing a polysubstituted allene carboxylic acid methyl ester compound based on CO2 and photocatalysis, which is based on a photocatalytic reaction system, takes CO2 as a carboxyl source, and is prepared through a 1, 3-enyne 1, 3-polysubstituted allene carboxylic acid methyl ester compound under the mild conditions of no photocatalyst and metal, so that the polysubstituted allene carboxylic acid methyl ester compound is obtained. According to the present invention, the efficient synthesis of the polysubstituted allene carboxylic acid derivative is achieved through the 1, 4-alkane carboxylation reaction, the method has advantages of good yield, wide substrate universality, suitableness for the reaction of a variety of functional groups, non-toxicity of the used reagent, and wide application prospect.

The invention relates to a novel spirocyclopropane tetronic acid derivative with insecticidal and acaricidal activity as well as preparation and application of the novel spirocyclopropane tetronic acid derivative. Specifically, the invention provides a compound as shown in a formula (I), and an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has obvious insecticidal and acaricidal activity, and can be used for developing novel crop insecticidal and acaricidal agents which are low in toxicity, efficient and environment-friendly. # imgabs0 #

The invention relates to preparation and application of a desoxyribonucleic acid and desoxyribonucleic acid derivative transdermal delivery system, and belongs to the technical field of biological medicine and skin care products. Desoxyribonucleic acid and derivatives thereof have the effects of resisting aging, repairing and the like, but are difficult to penetrate through a skin barrier due to large molecular weight and strong polarity. According to the invention, hydroxyethyl chitosan, desoxyribonucleic acid and derivatives thereof are combined through electrostatic interaction to form the nano-composite. The compound is small in particle size and can promote transdermal absorption through hair follicle or cuticle gaps. The preparation method is simple, does not need an auxiliary reagent, and comprises the step of mixing a hydroxyethyl chitosan solution and a deoxyribonucleic acid derivative solution. Experiments show that the compound significantly enhances the transdermal efficiency, and has the effects of promoting cell repair and proliferation and resisting inflammation. The composition can be used for skin care products, and is high in safety and wide in application prospect.

A pyrazole carboxylic acid derivative and the pharmaceutical use thereof, in particular, a compound represented by formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, and the use thereof in the preparation of a drug for treating sGC-related diseases.

Provided are: a liquid crystal aligning agent which contains two or more types of polyamic acids and which suppresses variations in the pretilt angle of a liquid crystal aligning film when stored at room temperature; a liquid crystal aligning film obtained from the liquid crystal aligning agent; and a liquid crystal display element. The liquid crystal aligning agent is characterized in that the liquid crystal aligning agent can form a liquid crystal alignment film with a pretilt angle of more than 0 degree and less than 3 degrees, and the liquid crystal aligning agent contains the following polymer (A) and polymer (B) or the following polymer (B) and polymer (B '). (Here, polymer (A) does not include polymer (B)) Polymer (A): a polyamic acid (A) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (a-1Ta) represented by formula (1Ta) and containing, as the structural unit derived from the diamine, a structural unit (a-1Da) represented by formula (1Da). Polymer (B): a polyamic acid (B) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (b-1Tb) represented by formula (1Tb), and containing, as the structural unit derived from the diamine, a structural unit (b-1Db) represented by formula (1Db). At least a part of the terminal of the polyamic acid (B) contains a non-amino group, the non-amino group is a functional group represented by structural formula (E), and the presence rate of the terminal amino group in the polyamic acid (B) is 60% or less based on the total terminal of the polyamic acid (B). Polymer (B '): a polyamic acid (B') having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing a structural unit (b-1Tb) represented by formula (1Tb) as the structural unit derived from the tetracarboxylic acid derivative and not containing a structural unit (a-1Da) represented by formula (1Ta), and the polyamic acid containing a structural unit (b-1Da) represented by formula (1Ta) as the structural unit derived from the diamine as the structural unit derived from the diamine. The polyamic acid (B) contains a structural unit (b-1Db) represented by formula (1Db) or a structural unit (b-1Db ') represented by formula (1Db'), and the content of terminal amino groups in the polyamic acid (B ') is greater than 60% based on the total terminals of the polyamic acid (B). (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) .

The present disclosure relates to analytical LC-MS / MS methods for second tier testing in Newborn Screening Program (2ndtier test or 2TT) for the simultaneous measuring of organic acids, acylcarnitines, aminoacids derivatives and acylglicines in dried blood spot samples.

The invention relates to a sustained-release pharmaceutical preparation of a fused tricyclic gamma-amino acid derivative and a preparation method of the sustained-release pharmaceutical preparation. The fused tricyclic gamma-amino acid derivative is a compound as shown in a formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof.

To provide a method for synthesizing a cyanide that is a precursor to a β-amino acid derivative having bulky optical activity, intended for peptide synthesis including a β-amino acid having bulky optical activity.SOLUTION: The present invention provides a method for synthesizing a cyanation product having a bulky tertiary alkylated structure and having optical activity, by reacting an α-haloamide having a bulky tertiary alkylated structure and having optical activity with a cyanohydrin in the presence of a copper catalyst.SELECTED DRAWING: None

The invention discloses a composition and a method for prolonging the shelf life of a liquid MDI product. The composition comprises (a) diphenylmethane diisocyanate (MDI), (b) at least one organophosphoric acid derivative with a structure shown in a formula (I), and (c) at least one metal carbonyl compound with a structure shown in a formula (II). The method provided by the invention can inhibit the formation of the MDI dimer, and especially prominently, can improve the solubility of the MDI dimer in a liquid MDI product, reduce the freezing point of the liquid MDI product, prolong the storage life of the liquid MDI product, and improve the storage and transportation stability and operation convenience of the liquid MDI product.

The invention relates to an amino acid derivative carrier as well as a preparation method and application thereof, and belongs to the technical field of biology, and the preparation method of the amino acid derivative carrier comprises the following steps: providing a cationic amino acid monomer and a neutral-polyanion block polymer template; a cationic amino acid monomer, a neutral-polyanion block polymer template, a cross-linking agent and a photoinitiator are mixed and react under the irradiation of ultraviolet light to obtain an amino acid derivative carrier, and the amino acid derivative carrier is cationic nanogel. The amino acid derivative carrier prepared by the preparation method disclosed by the invention can be used as a nucleic acid drug delivery carrier, and has the advantages of strong nucleic acid loading capacity, high transfection efficiency, safety and the like.

The invention provides a liquid crystal aligning agent, a liquid crystal alignment film and a liquid crystal display element, wherein the liquid crystal aligning agent reduces deviation of torsion angles of liquid crystals, suppresses flicker and has high transmittance. The liquid crystal aligning agent contains: a polymer (A): a polyamic acid (A) having a structural unit derived from a tetracarboxylic acid derivative including a structural unit represented by formula (1Ta) and a structural unit derived from a diamine including a structural unit represented by formula (1Da), wherein at least a part of the terminal of the polyamic acid (A) contains a non-amino group as a functional group represented by formula (E); polymer (B): a polyamic acid (B) having a structural unit derived from a tetracarboxylic acid derivative including a structural unit represented by formula (1Tb) and a structural unit derived from a diamine. The present invention is characterized by comprising, as constituent units derived from a diamine, a constituent unit represented by formula (1Db1), a constituent unit represented by formula (1Db2), and a constituent unit represented by-N (Z)-YU-N (Z)-(YU represents a divalent organic group having a urea bond). # imgabs0 #

The invention relates to a non-gadolinium magnetic resonance contrast agent and a preparation method thereof, and belongs to the field of contrast agents. The invention aims to provide a non-gadolinium contrast agent with high biological safety aiming at the risks of renal fibrosis and cerebral deposition existing in a gadolinium-based magnetic resonance contrast agent. The invention provides a phosphate group modified non-gadolinium magnetic resonance contrast agent. The phosphate group modified non-gadolinium magnetic resonance contrast agent consists of a ligand of a phosphate group substituted trans-cyclohexanediamine tetraacetic acid derivative (tmPCDTA or tqPCDTA) and metal ions Fe < 3 + > or Mn < 2 + >, the contrast agent disclosed by the invention is high in biological safety: endogenous Fe < 3 + > / Mn < 2 + > is used for replacing gadolinium, and cell experiments prove that the survival rate of 4T1 cells is not influenced at the concentration of 500 mu M; clinical applicability is high, kidney excretion is rapid, bladder signals are enhanced 3-5 minutes after mouse intravenous injection, and liver retention is avoided.

The application belongs to the technical field of organic synthesis, and particularly relates to a synthesis method of chiral N-alkyl amino acid derivatives. The synthesis method is improved on the basis of the synthesis method of chiral N-alkyl amino acid derivatives in the prior art, has mild reaction conditions, high yield, is beneficial to industrial large-scale production, and solves the amplification effect of the synthesis method in the prior art.

The present invention provides a liquid crystal aligning agent that can form a liquid crystal alignment film having excellent mechanical properties, and can provide a liquid crystal element that exhibits good liquid crystal alignment properties, a high voltage holding ratio, and excellent reliability. [Solution] A liquid crystal aligning agent contains polymer (A), which is at least one selected from the group consisting of polyamic acid, polyamic acid ester, and polyimide, and is obtained using two or more tetracarboxylic acid derivatives including a compound represented by formula (1), and satisfies at least one of requirements 1 and 2. Requirement 1: Further, polymer (B) different from polymer (A) is contained. Requirement 2: Two or more types of polymer (A) are contained. In formula (1), Y 1 and Y 2 are each independently a tetravalent organic group. 1 is a divalent organic group. TIFF0007758236000037.tif24168

Described is a compound for substituting amino acids of proteins or peptides, wherein the compound has the formula (1)wherein the stereocenter C1* represents CH that either results in the D- or L-form of the compound of formula (1); A− is a negatively charged ion compensating the positive charge; X1 is H or an amine protecting group; X2 is OH, an ester residue or an amide residue or an activated carboxylic acid derivate to be used for the formation of an amide bond; Y1, Y2 and Y3 are independently from each other a C1-C6 alkyl, and Z1 and Z2 are independently from each other a nucleobase, a C1 to C16 alkyl group, an aromatic residue or a heteroaromatic residue, wherein the aromatic residue or the heteroaromatic residue contains one 5, 6, or 7-membered ring or two condensed 5, 6, or 7-membered rings sharing two carbon atoms, wherein the aromatic residue or the heteroaromatic residue can be substituted by a linear or branched C1 to C16 alkyl group and / or a further aromatic group. Furthermore, a method for preparing this compound and proteins and peptides containing this compound are disclosed.

The present invention relates to a novel synthesis of 2-fluoromethyl acrylate (MFA), which is a key precursor for the production of Veltassa® (Patiromer). The process according to the invention obtains MFA (III) by reacting an alpha-substituted beta-hydroxy propionic acid derivative (I) via one or more intermediate steps involving one or more alpha-, beta-substituted propionic acid derivatives (II).

To provide an oral composition containing dl-α-tocopheryl 2-L-ascorbyl phosphate diester alkali metal salt and cetylpyridinium chloride, with reduced photodegradation of the dl-α-tocopheryl 2-L-ascorbyl phosphate diester alkali metal salt.SOLUTION: An oral composition includes dl-α-tocopheryl 2-L-ascorbyl phosphate diester alkali metal salt, cetylpyridinium chloride, and at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof.SELECTED DRAWING: None

The invention provides a method for synergistically removing impurities through pH regulation and complexing of ionic rare earth ore leachate, the ionic rare earth ore leachate is stirred and mixed uniformly, a plant polyphenol sulfonic acid derivative complexing agent is added, the complexing agent is prepared through sulfonation, neutralization, concentration and drying by taking gallic acid as a raw material, and the complexing agent can automatically regulate the pH value of the solution and stabilize the pH value at 5.1-5.3; under the condition, phenolic hydroxyl groups, carboxyl groups and sulfonic functional groups in complexing agent molecules preferentially form stable precipitates with impurity ions such as Al < 3 + > and Fe < 3 + > in the leachate, and the complexing effect with rare earth ions (RE < 3 + >) is weak; and after the reaction is completed, carrying out solid-liquid separation to obtain the purified leachate and impurity-containing precipitation slag. The method solves the problem of ammonia nitrogen pollution caused by use of ammonium bicarbonate, ammonia water and other ammonium salts in the traditional process, is a novel method with high impurity removal rate, simple process flow and environmental friendliness, and is suitable for industrial application.

The invention relates to the technical field of organic chemical synthesis, and discloses a method for preparing a chlorogenic acid derivative by condensing chlorogenic acid and a bifunctional amino acid derivative, which comprises the following step: in the presence of EDCI and HOBt, reacting chlorogenic acid with the bifunctional amino acid derivative in a DMF solvent to obtain the chlorogenic acid derivative. The method does not need to protect hydroxyl, the synthesis steps are simple, and the reaction is green, environment-friendly and pollution-free.

This invention discloses a 1,6-diamino-dibenzo[a,o]perylene-7,16-dione-2,5-disulfonic acid derivative, its preparation method, and its application. Using a vat dye derivative PR177 as the parent material, a 4,4'-diamino-1,1'-dianthraquinone-3,3'-disulfonic acid derivative is formed by the Ullmann condensation of a 1-amino-4-bromoanthraquinone-2-sulfonic acid derivative. This derivative is then cyclically closed via the McMurray reaction to form the 1,6-diamino-dibenzo[a,o]perylene-7,16-dione-2,5-disulfonic acid derivative. This allows for direct dyeing without the use of sodium hydrosulfite. Compared to soluble vat dyes, it is stable when exposed to air. Furthermore, due to its good planarity, it exhibits excellent dyeing performance as an acid dye. It combines the advantages of good directness of vat dyes and good water solubility of acid dyes, especially showing excellent color fastness and exhaustion rate in wool dyeing.

The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clindamycin and artesunate for the treatment of malaria, in particular for the acute therapy of cerebral malaria, and to an associated dosage, in particular for the patient group of children.

The invention belongs to the technical field of development of anti-inflammatory and antioxidant drugs, and discloses a gallic acid derivative as well as a preparation method and application thereof. The gallic acid derivative is a compound with a structure as shown in a formula 2 or a pharmaceutically acceptable salt or solvent compound thereof. The gallic acid derivative belongs to novel compounds, the compounds are designed and successfully synthesized for the first time, and meanwhile, the structures of the compounds are represented; the preparation method of the gallic acid derivative is simple and convenient to operate, and the compounds can be rapidly synthesized; research finds that the gallic acid derivative has good anti-inflammatory and antioxidant activity, and shows good application prospects in treatment of inflammation and oxidative stress. # imgabs0 #